Intended use

  • The human I-FABP ELISA kit is to be used for the in vitro quantitative determination of human I-FABP in serum, plasma, urine, and cell culture supernatant samples.
  • The analysis should be performed by trained laboratory professionals and is designed for research purposes only, not intended for diagnostic purposes.

  • Methodology:  Sandwich ELISA with a recombinant standard
  • Time:  3½ hours
  • Minimum:  47 pg/mL
  • Range: 47-3,000 pg/mL
  • Working volume: 100 µl/well
  • Sample:  plasma, urine (recommended dilution of at least 1:2) and cell culture supernatant
    Note:  most reliable results are obtained with citrate or heparin plasma


  • Wash buffer 40x
  • Sample Dilution buffer 10x
  • Dilution buffer 10x
  • Standard
  • Tracer, biotinylated
  • Streptavidin-peroxidase 100x
  • TMB substrate
  • Stop solution
  • Pre-coated microtiter plate, 1 plate

Fatty acid-binding proteins (FABPs) are a class of cytoplasmic proteins that bind long-chain fatty acids. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport, and metabolism. There are at least nine distinct types of FABPs, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of damaged cells, leading to a rise in serum levels.

Intestinal FABP (I-FABP) is specifically localized in the epithelial cells of the small and large intestine tissue. Normally, I-FABP is undetectable in serum, but it has been shown that I-FABP is released into the circulation following small intestine mucosal injury.  I-FABP has emerged as a potential non-invasive marker for evaluating the loss of gut wall integrity and could be helpful as a biomarker for researching intestinal damage in diseases like bacteremic abdominal sepsis, necrotizing enterocolitis, and celiac disease.  I-FABP in the serum also may be an indicator of gut dysfunctions associated with severe insulin resistance and Type 2 Diabetes.